ZÃ¼rich-Schlieren, Switzerland, 09 December, 2014. Molecular Partners announced today that Janssen Biotech, Inc. (â€œJanssenâ€) has exercised an option to secure exclusive rights to a multi-specific DARPin program. As a compensation for the option exercise, Molecular Partners will receive a milestone payment of USD 2 million.
Monthly Archives: December 2014
Zurich-Schlieren, December 5, 2014. Molecular Partners AG announces that the total offer size of the initial public offering (â€œIPOâ€) amounts to CHF 106.2 million, of which gross proceeds from the primary shares issued are CHF 104.1 million. The Joint Bookrunners of Molecular Partners’ IPO have partially exercised the over-allotment option yesterday at the offer price of CHF 22.40 per share.